Company Overview and News

22
Be Wary Of Glu Mobile Stock As It Runs To Decade Highs

2018-10-11 investorplace
Mobile gaming company Glu Mobile (NASDAQ:GLUU) has been on fire in 2018. A comeback in the mobile gaming market has coupled with a re-imagined Glu gaming portfolio, and powered robust bookings growth so far this year. This robust growth has pushed GLUU stock up 70% year-to-date.
FB TWTR NFLX GLUU SNAP

77
Progenics Pharmaceuticals stock halted for news pending

2018-10-05 marketwatch - 4
Progenics Pharmaceuticals Inc. shares fell in the extended session Wednesday after the cancer drug company said one of its imaging agents was not sensitive enough to detect prostate cancer in a clinical study. Progenics shares fell 19% after hours, following a 1.6% decline to close the regular session at $7.30. The company said a late-stage clinical trial found its so-called "1404" imaging agent needed to positively detect prostate cancer with a 60% or more sensitivity but did so with a 47% to 51% range.
NKTR MIK OPK FOLD PGNX GLUU BABY

8
JAKKS Pacific Strategic Efforts Bode Well: Should You Hold?

2018-09-26 zacks - 1
JAKKS Pacific, Inc.’s (JAKK - Free Report) focus on diversifying its footprint outside the United States along with a string of acquisitions over the past several years bodes well. This is quite evident from the company’s share price performance in the past six months. The stock has surged 25.6%, outperforming the industry’s 15.6% rally. However, decrease in demand for its product and rising costs raise concerns.
MAT JAKK HAS TWX TWC GLUU

2
Mohawk's (MHK) Downtrend Continues: What's Hurting the Stock?

2018-09-25 zacks - 1
Despite undertaking several strategic measures to drive performance, Mohawk Industries, Inc. (MHK - Free Report) failed to impress investors. The company’s shares have declined 26% in a year’s time compared with the industry’s decline of 20.7%. Let’s delve deeper and try to assess what’s taking this Zacks Rank #5 (Strong Sell) company down the hill. Rising Costs Hurt Profit Margins Mohawk is bearing the brunt of higher raw materials, labor, energy and fuel-related costs, which impacted its profitability.
CRI MHK GLUU CAL

 
Is Glu Mobile (GLUU) Outperforming Other Consumer Discretionary Stocks This Year?

2018-09-25 zacks
The Consumer Discretionary group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Glu Mobile (GLUU - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Consumer Discretionary sector should help us answer this question.
GLUU

 
Here's Why Momentum Investors Will Love Glu Mobile (GLUU)

2018-09-20 zacks
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction.
GLUU

12
UPDATE 1-Tencent investment exec quits amid Chinese gaming industry turmoil

2018-09-19 reuters
(Reuters) - Tencent Holdings Ltd executive Jonathan Lai, who led the company’s investments into Western digital entertainment firms, has left to join a New York-based investment manager, according to his LinkedIn profile.
BABA 0700 NFLX GLUU ATVI

4
Eventbrite Is Fueling The Experience Economy

2018-09-17 seekingalpha
The Experience Economy resulting from it is reinforced by social media and fear of missing out for the mobile-first generations.
MSG LYV GLUU

1
Mattel (MAT) Continues to Improve Board to Revive Business

2018-09-14 zacks
Mattel, Inc. (MAT - Free Report) is likely to continue with its long-standing struggle that stemmed from soft consumer demand and sales crunch. Not exempting the prevalent fate of U.S. toymakers, the company is suffering from consequences of the Toys ‘R’ Us liquidation.
MAT HAS CY GLUU

1
Take Two Strengthens Competitive Position, Launches NBA 2K19

2018-09-12 zacks
Take Two Interactive Software’s (TTWO - Free Report) 2K division recently announced the availability of NBA 2K19. The cover of the standard edition of the latest title of this popular franchise features Giannis Antetokounmpo and is now available for $59.99. 2K also launched an NBA 2K19 20th Anniversary Edition with LeBron James on the cover. The package includes the NBA 2K19 game, 100,000 Virtual Currency, MyTEAM cards, LeBron-themed digital items for MyPLAYERs and more for $99.
EA TTWO LB GLUU

2
Activision Blizzard (ATVI) Looks Good: Stock Adds 7.1% in Session

2018-09-12 zacks
Activision Blizzard, Inc. (ATVI - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $68.93 to $74.91 in the past one-month time frame.
CY GLUU ATVI

1
Hyatt (H) Expands Hyatt Place Select-Service Brand in France

2018-09-12 zacks
Hyatt Hotels Corporation (H - Free Report) recently announced a franchise agreement with a subsidiary of Matmut S.A.M. to open a luxury hotel in Rouen, France. Notably, the new property will be managed by Cycas Hospitality and will mark Hyatt’s first hotel in the capital of Normandy and second Hyatt Place property in France. The 78 guest-roomed hotel is expected to open in 2021 and will join the dual-branded Hyatt Place and Hyatt House hotels in Europe.
H CRI GLUU CAL

1
Hasbro Banks on Product Innovation, Partners With Epic Games

2018-09-11 zacks
Hasbro, Inc. (HAS - Free Report) , like most traditional toy makers, has been bearing the brunt of soft consumer demand and a sales crunch. In an effort to navigate challenges, the company announced a partnership with Epic Games, a leading game developer to introduce a range of Fortnite version of "Monopoly," and “Nerf Blasters”. The Monopoly variant of the Fortnite Battle Royale will be released this fall, while the Nerf Blasters are scheduled to be unveiled in 2019.
HAS CRI GLUU CAL

24
The Zacks Analyst Blog Highlights: Caterpillar, D.R. Horton, Bristol-Myers Squibb, athenahealth and BJ's Restaurants

2018-09-07 zacks
Chicago, IL – September 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caterpillar Inc. (CAT - Free Report) , D.R. Horton, Inc. (DHI - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) , athenahealth, Inc.
ARLP CCR CAT GLUU SHAK TPVZ LADR TPVY GTIM GM JMP CVGI CATR JMPB JMPC JMPD ALLY BJRI DHI TPVG ATHN FG

27
The Zacks Analyst Blog Highlights: Chevron, U.S. Bancorp, Kraft Heinz, General Mills and Workday

2018-09-07 zacks
Chicago, IL – September 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chevron (CVX - Free Report) , U.S. Bancorp (USB - Free Report) , Kraft Heinz (KHC - Free Report) , General Mills (GIS - Free Report) and Workday (WDAY - Free Report) .
ARLP CCR GIS XOM WDAY GLUU USB SHAK TPVZ LADR TPVY GTIM GM JMP CVGI JMPB JMPC JMPD ALLY CVX KHC TPVG FG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to GLUU / Glu Mobile, Inc. on message board site Silicon Investor.

Glu Mobile, Inc. (GLUU) Glu Mobile, Inc. (GLUU) Glu Mobile, Inc. (GLUU)
CUSIP: 379890106